Reduction of parasite levels in patients with uncomplicated malaria by treatment with HE2000

• Main Authors: James M. Frincke, Dwight R. Stickney, Nanette Onizuka-Handa, Armando Garsd, Christopher Reading, Srivicha Krudsood, Polrat Wilairatana, Sornchai Looareesuwan
• Other Authors: Hollis-Eden Pharmaceuticals, Inc.
• Format: Article
• Published: 2018
• Subjects: Immunology and Microbiology; Medicine
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/24585
• Institution: Mahidol University

16α-Bromoepiandrosterone (HE2000) is a synthetic androstane steroid that has immune effects in preclinical models of malaria, tuberculosis, and infection with human immunodeficiency virus. In pilot studies, 42 patients with confirmed uncomplicated Plasmodium falciparum malaria were treated with a seven-day course of HE2000 by either buccal administration or intramuscular injection. Of the 42 patients, 41 showed a 50% reduction in blood levels of parasites, the primary endpoint of the study. Of these, 32 (76%) cleared malaria parasites below detectable levels. All febrile patients became afebrile by the end of treatment. There was no reduction in gametocyte forms. Adverse events were transient and mild to moderate in intensity. The anti-malarial response was generally similar with either the intramuscular or buccal routes of administration. HE2000 shows a safety profile and pharmacologic activity worthy of further investigation to understand its role in the treatment of malaria, perhaps in combination with anti-malarial agents. Copyright © 2007 by The American Society of Tropical Medicine and Hygiene.